There are 360 resources available
The immune microenvironment of primary and metastatic brain tumours
Presenter: Andrea Anichini
Session: The future of CNS tumors: Learning from failures and driven by biology
Resources:
Slides
Webcast
Invited Discussant
Presenter: Natasha Leighl
Session: Proffered Paper session
Resources:
Slides
Webcast
Second vote and conclusions
Presenter: Stephen Schoenberger
Session: Cancer vaccines: Promise or dead end?
Resources:
Webcast
Future perspectives on brain tumours' treatment
Presenter: Michael Weller
Session: The future of CNS tumors: Learning from failures and driven by biology
Resources:
Slides
Webcast
56O - A randomized, controlled, multicenter phase II trial of camrelizumab combined with albumin-bound paclitaxel and cisplatin as neoadjuvant treatment in resectable stage IIIA and IIIB(T3N2) non-small-cell lung cancer
Presenter: Jie Lei
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: Anna Di Giacomo
Session: The future of CNS tumors: Learning from failures and driven by biology
Resources:
Webcast
1O - IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)
Presenter: Enriqueta Felip
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
Invited Discussant
Presenter: Solange Peters
Session: Proffered Paper session
Resources:
Slides
Webcast
58O - Real-world overall survival (OS) with durvalumab (D) after chemoradiotherapy (CRT) in patients (pts) with unresectable Stage III non-small-cell lung cancer (NSCLC): interim analysis from the PACIFIC-R study
Presenter: Nicolas Girard
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast
57O - Randomized Double-Blind Phase II Trial (PERLA) of Dostarlimab (dostar) + Chemotherapy (CT) vs Pembrolizumab (pembro) + CT in Metastatic Non-Squamous NSCLC: Primary Results
Presenter: Solange Peters
Session: Proffered Paper session
Resources:
Abstract
Slides
Webcast